Premium
Prognostic models for renal cell carcinoma recurrence: External validation in a Japanese population
Author(s) -
Utsumi Takanobu,
Ueda Takeshi,
Fukasawa Satoshi,
Komaru Atsushi,
Sazuka Tomokazu,
Kawamura Koji,
Imamoto Takashi,
Nihei Naoki,
Suzuki Hiroyoshi,
Ichikawa Tomohiko
Publication year - 2011
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/j.1442-2042.2011.02812.x
Subject(s) - nomogram , medicine , concordance , renal cell carcinoma , nephrectomy , stage (stratigraphy) , oncology , pathological , t stage , urology , overall survival , kidney , paleontology , biology
The aim of the present study was to compare the accuracy of three prognostic models in predicting recurrence‐free survival among Japanese patients who underwent nephrectomy for non‐metastatic renal cell carcinoma (RCC). Patients originated from two centers: Chiba University Hospital ( n = 152) and Chiba Cancer Center ( n = 65). The following data were collected: age, sex, clinical presentation, Eastern Cooperative Oncology Group performance status, surgical technique, 1997 tumor–node–metastasis stage, clinical and pathological tumor size, histological subtype, disease recurrence, and progression. Three western models, including Yaycioglu's model, Cindolo's model and Kattan's nomogram, were used to predict recurrence‐free survival. Predictive accuracy of these models were validated by using Harrell's concordance‐index. Concordance‐indexes were 0.795 and 0.745 for Kattan's nomogram, 0.700 and 0.634 for Yaycioglu's model, and 0.700 and 0.634 for Cindolo's model, respectively. Furthermore, the constructed calibration plots of Kattan's nomogram overestimated the predicted probability of recurrence‐free survival after 5 years compared with the actual probability. Our findings suggest that despite working better than other predictive tools, Kattan's nomogram needs be used with caution when applied to Japanese patients who have undergone nephrectomy for non‐metastatic RCC.